Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROS1 | P08922 | 10/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 3/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL988254 | 0.89 | ROS1 (0.47) | ROS1FLT3KDM4CCTSAALK | |
| SCHEMBL12678157 | 0.89 | ROS1 (0.70) | ROS1FLT3KDM4CGRM5CTSA | |
| SCHEMBL987974 | 0.87 | ROS1 (0.61) | ROS1FLT3ALKMETTGFBR1 | |
| SCHEMBL989192 | 0.87 | ROS1 (0.58) | ROS1FLT3ALKMETTGFBR1 | |
| SCHEMBL989216 | 0.86 | FLT3 (0.61) | ROS1FLT3GRM5ALKMET | |
| SCHEMBL988727 | 0.86 | ROS1 (0.63) | ROS1FLT3ALKMETMAPKAPK2 | |
| SCHEMBL987992 | 0.84 | ROS1 (0.69) | ROS1FLT3ALKMETMAPKAPK2 | |
| SCHEMBL12678164 | 0.82 | ROS1 (0.71) | ROS1FLT3KDM4CGRM5ALK | |
| SCHEMBL990290 | 0.81 | ROS1 (0.67) | ROS1FLT3 | |
| SCHEMBL988552 | 0.81 | FLT3 (0.61) | ROS1FLT3GRM5ALKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015395-A1 | PYRAZOLE COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST ROS KINASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-01-20 | — | — | US | claimed |
| US-8273880-B2 | Pyrazole compounds with inhibitory activity against ROS kinase | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-09-25 | — | — | US | disclosed |
| US-8273880-B2 | Pyrazole compounds with inhibitory activity against ROS kinase | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-09-25 | — | — | US | disclosed |
| US-8273880-B2 | Pyrazole compounds with inhibitory activity against ROS kinase | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-09-25 | — | — | US | disclosed |
| US-20110015395-A1 | PYRAZOLE COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST ROS KINASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-01-20 | — | — | US | disclosed |
| US-20110015395-A1 | PYRAZOLE COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST ROS KINASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-01-20 | — | — | US | disclosed |
| US-20110015395-A1 | PYRAZOLE COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST ROS KINASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015395-A1 | PYRAZOLE COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST ROS KINASE | ROS1, PDPK1, MAP3K19 | ROS1 1/4885FLT3 206/4885KDM4C 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.